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Background: Malaria Is A Life-Threatening Pathology In Africa. Plasmodium Falciparum And Plasmodium Vivax
Attract The Most Focus Because Of Their High Prevalence And Mortality. Knowledge About The Prevalence Of
The Cryptic Pathogens Plasmodium Ovale And Plasmodium Malariae Is Limited. Thanks To Recombinant Tools,
Their Seroprevalence Was Measured For The First Time, As Well As The Prevalence Of Mixed Infections In A
Malaria-Asymptomatic Population In Benin, A Malaria-Endemic Country.
Methods: A Panel Of 1,235 Blood Donations Collected Over Ten Months In Benin Was Used For Validation Of The
Recombinant Tools. Recombinant P. Falciparum, P. Malariae, P. Ovale MSP1, And P. Falciparum AMA1 Were
Engineered And Validated On A Biobank With Malaria-Infected Patients (N = 144) Using A Species-Speific ELISA Test
(Recelisa). Results Were Compared To An ELISA Using A Native P. Falciparum Antigen (NatELISA).
Results: Among Microscopically Negative African Blood Donors, 85% (1,050/1,235) Present Antibodies Directed
To Native P. Falciparum, 94.4% (1,166/1,235) To rPfMSP1 And rPfAMA1, 56.8% (702/1,235) To rPoMSP1, 67.5%
(834/1235) To rPmMSP1 And 45.3% Of The Malaria Seropositive Population Had Antibodies Recognizing The
Three Species.
Conclusion: A High Rate Of Antibodies Against P. Ovale And P. Malariae Was Found In Asymptomatic Blood
Donors. The Proportion Of Mixed Infections Involving Three Species Was Also Unexpected. These Data Suggest That
Determining Seroprevalence For These Cryptic Species Is An Appropriate Tool To Estimate Their Incidence, At The
Eve Of Upcoming Anti-P. Falciparum Vaccination Campaigns.
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Malaria is one of the most life-threatening diseases in the
world. In 2010, 219 million cases were reported globally
[1], leading to 660,000 deaths, mostly of children under
five years old. Five parasitic species cause human malaria
(Plasmodium falciparum, Plasmodium vivax, Plasmodium
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article, unless otherwise stated.which are transmitted by the bite of infected Anopheles
mosquitoes. Despite huge efforts to control the disease,
resurgence has been observed in many countries due to
climate instability, global warming, civil disturbances, drug
resistance, and increasing travel between endemic and
non-endemic areas [2].
Identifying the most affected countries’ direct resources
and validating control measures is essential to reducing
malaria’s incidence (target: 75% by 2015) [1]. Epidemio-
logical surveillance seeks to assess malaria’s prevalence over
time and identify the species’ geographical distribution.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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gress [3]; not so for P. malariae and P. ovale, where
prevalence has been insufficiently investigated. To further
complicate matters, low levels of parasitaemia and mixed
infections can affect diagnosis of P. malariae and P. ovale.
Birkenmeyer et al. recently sequenced genes encoding
major erythrocyte stage markers of P. malariae and
P. ovale, demonstrating the feasibility of Merozoite Sur-
face Protein 1 (MSP1) recombinant production [4] and
use in ELISA to detect antibodies against P. malariae and
P. ovale [5]. Proteins were selected according to their
ability to elicit antibody production and chosen from
among previously described vaccine candidates. MSP1
is one of the main surface proteins at the merozoite
stage expressed in all Plasmodium species and plays a
role in red blood cell (RBC) invasions [6]. Plasmodium
falciparum AMA1 is a blood-stage antigen that aids in
orienting the merozoite during invasion of RBC. Anti-
AMA1 antibodies tend to be present in individuals who
have acquired natural immunity [7].
Estimation of malaria prevalence is historically done
by optical microscopy but a sensitivity of 50 parasites/μL
is insufficient [8]. Further, highly trained staff is neces-
sary, rendering this approach unsuitable for large-scale
monitoring. Rapid diagnostic tests and PCR methods are
also inappropriate for broad evaluation. ELISA antigen
detection of Plasmodium lactate dehydrogenase (pLDH)
has been documented as a valuable tool for assessing
prevalence in a blood donor population [9]. However,
detectability is limited to one parasite/μL and the assay
is inappropriate for P. malariae and P. ovale identifica-
tion. Furthermore, various factors influence the direct
detection of parasites, among them parasite clearance
due to acquired immunity, drug treatment, season vari-
ability and sporadic transmission in low-transmission
areas. For this reason, seroprevalence measurement has
been explored as an accurate tool for estimating trans-
mission intensity and the potential effects of any mea-
sures used to control (and ultimately eliminate) malaria
[10]. Indeed, antibodies against the four Plasmodium
species appear within days or weeks of erythrocyte inva-
sion, and can persist for months or years reflecting
exposure to the parasites [11].
Immunofluorescence detection of malaria antibodies
was until recently the gold standard [12], but is unsuitable
for high-throughput screening. ELISA-based seropreva-
lence screening is a potentially useful epidemiological
tool [13]. An immuno-enzymatic assay combining the
crude P. falciparum antigen and recombinant P. vivax
proteins was already developed, exhibiting high specifi-
city and analytical sensitivity (96.7 and 93.1%, respec-
tively) in the detection of Plasmodium antibodies [14].
However, this technique could not discriminate be-
tween the four species.In this work, the identification and production of
recombinant proteins from P. falciparum, P. ovale and
P. malariae was reported to establish an ELISA test for
the detection of Plasmodium species-specific antibodies.
Immunoassay performances were first assessed in a
population of Plasmodium-infected French travellers.
For the first time, the distribution of the P. malariae and
P. ovale in endemic malaria areas in Benin (Western
Africa) was evaluated in a blood donor population.
Methods
Samples from Plasmodium-infected patients for sensitivity
calculation
Malaria patients returning from endemic countries sera
(n = 144), diagnosed and referred at the Strasbourg
University Hospital were used for the study. All patients
reported fever and were microscopically diagnosed posi-
tive for P. falciparum (n = 106), P. malariae (n = 12), or
P. ovale (n = 26). All results were confirmed by PCR.
Every patient was treated and the samples anonymized.
This population was used to determine the recombinant
ELISA assay’s clinical sensitivity and positive predictive
value.
Negative samples
Blood donor samples were collected at the Etablissement
Français du Sang d’Alsace (EFS Alsace). Donors were
classified as unexposed-to-malaria (192 samples) if their
questionnaire responses indicated never having travelled
to an endemic area. These samples were used to calcu-
late the test’s specificity and negative predictive value.
Samples from Beninese blood donors
Plasma and total blood samples from blood donors with-
out apparent malaria symptoms (n = 1,235) were col-
lected over ten months (May 2009 to February 2010) in
six Beninese departmental blood centres [9]. Each donor
signed a consent form, and both the Direction of Benin
National Blood Transfusion Agency and the Research
Ethics Committee of the Republic of Benin validated the
protocol. The collection period was divided into a long
rainy season (LRS) from May to July (n = 387), a short
dry season (SDS) from August to September (n = 217), a
short rainy season (SRS) from October to November
(n = 408), and a long dry season (LDS) from December
to February (n = 223). Two expert biologists performed
parasitic examinations on all samples via microscopy on
a May-Grünwald-Giemsa-stained thin and thick film.
Positivity for Plasmodium was detected microscopically
in 290 donors, who were used to assess the performance
of the recombinant proteins. ELISA tests using a native
P. falciparum antigen and recombinant proteins from
P. falciparum, P. ovale and P. malariae were used to as-
sess seroprevalence in the Beninese samples. Five donors
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SRS); they were kept due to the low number of repeat
donors, since they were positive for malaria antibodies.
Recombinant proteins
Nucleotide constructs encoding 373 AA (amino acids) of
P. falciparum MSP1 (Accession Number XP_001352170.1),
356 AA of P. ovale MSP1 (ACZ51239.1), and 350 AA of
P. malariae MSP1 (ACZ51237.1) corresponding to the
C-terminus region of the protein (42 kD) and a nucleotide
construct encoding 448 AA of P. falciparum AMA1
(XP_001348015.1) were commercially synthesized with an
Escherichia coli codon bias (Genscript, Piscataway, NJ,
USA). Consensus sequences derived from the alignment of
several strains for each species and each protein were used
for the design of synthetic genes. All genes were inserted
in an expression vector containing a Maltose binding pro-
tein fusion partner pMAL-c2X® (New England BioLabs,
Ipswich, MA, USA), produced in E. coli expression hosts
and purified on amylose resin and DEAEsepharose ®(GE
healthcare, Uppsala, Sweden).
Plasmodium species DNA detection by PCR
Detection of P. falciparum based on the amplification of
the STEVOR gene, a subtelomeric multiple copy gene,
was performed according to Filisetti et al. [15]. The
other infecting Plasmodium species were identified using
a genus and species-specific nested PCR, in addition to a
PCR tailored to a specific P. ovale subspecies (P. ovale
wallikeri) [16].
ELISA using Plasmodium falciparum native antigen
(NatELISA) and recombinant protein (RecELISA)
Antibody screening was performed using an in-house
ELISA test derived from a commercial assay (DiaMed)
[14]. Native P. falciparum antigen produced from in vitro
culture (NatELISA) [17] or recombinant rMSP1 for
P. ovale, P. malariae, P. falciparum and rP. falciparum
AMA1 (RecELISA) were immobilized on 96-well plates
overnight at 4°C in coating buffer and blocked for one
hour with PBST (Phosphate Buffered Saline with Tween
0.05%) containing 1% BSA (bovine serum albumin)
(Merck, Darmstadt, Germany). After washing with PBST,
200 μl of diluent buffer (PBST with BSA 0.1%) were dis-
pensed into each well and 10 μl of serum were incubated
for one hour at 37°C. On the same plate, 10 μL of positive
controls specific for each species and negative controls in
triplicate were added. After three washes with PBST,
100 μl of horseradish peroxidase labelled monoclonal
rabbit anti human IgG (Sigma-Aldrich, St Quentin,
France) were incubated for 30 min at 37°C. After three
washes with PBST, 100 μl of TMB plus substrate solution
(Tetramethylbenzidine) (Kem-en-tec, Denmark) were in-
cubated for 15 min at 37°C and the reaction was stoppedwith 50 μl of 0.5 M sulphuric acid. The absorbance was
read within 30 min at 450 nm against 620 nm. Test va-
lidation required the positive OD to be >0.500 and the
negative OD <0.200. The cut-off value was set at three-
fold the negative control wells’ average OD. The anti-
body (Ab) index of each sample was defined as ratio of
its OD value and the cut-off value. The sample was
considered positive if the Ab index was >0.7, and nega-
tive if the Ab index was ≤0.7.
All recombinant assays were performed on an EVOLIS
Microplate System (Bio-Rad) at the Department of
Microbiology of the Hôpitaux Universitaires de Strasbourg.
Statistical analysis
Statistical differences between P. falciparum native antigen
ELISA (NatELISA) and recombinant ELISA (RecELISA)
performances were analysed using Chi-squared and t-tests,
as detailed in the Results section, below. Significant diffe-
rences in antibody prevalence depending on the season,
observed during follow-up, were assessed using the
Chi-squared test. A p-value of less than 0.05 was con-
sidered significant. Correlation between antibody titre
and ELISA index for the recombinant antigens was cal-
culated using the Pearson correlation test. (GraphPad
Prism 6.0 software, La Jolla, CA, USA).
Results
Performance of the RecELISAs
The assay was first evaluated on 144 plasma samples from
malaria patients diagnosed using microscopy and con-
firmed by PCR. The RecELISA performed better than the
NatELISA, which used a P. falciparum native antigen
(Table 1). Recombinant proteins from other Plasmodium
species presented a good sensitivity; only three of 26
P. ovale cases were missed, and every P. malariae infec-
tion was detected. The combined performance of the
three RecELISAs (using recombinant proteins from three
species) was superior to that of the NatELISA (Table 2).
On the other hand, the RecELISA failed to detect nine
positive cases, most of them also missed by the NatELISA
(Table 3). Three of the nine missed infections were
P. ovale cases, while six were P. falciparum. However,
eight cases were detected exclusively by RecELISA. Four
of those were P. ovale and one was P. malariae; the
three others were P. falciparum infections. Overall
specificity was 97.9%, calculated on 192 unexposed to
malaria blood donors.
Antibody prevalence in Beninese blood donors
The recombinant antigens were used to evaluate
species-specific antibody prevalence in a panel of Beni-
nese blood donors. A population of blood donors with
microscopically detectable Plasmodium infections was
isolated from a previous study [9]. Anti-P. falciparum
Table 1 Evaluation of the performance of ELISA using species-specific recombinant Plasmodium proteins (RecELISA) in
comparison to an ELISA using P. falciparum native antigen (NatELISA) in a population of malaria-infected travellers
(n = 144): 106 Plasmodium falciparum patients; 26 Plasmodium ovale patients and 12 Plasmodium malariae patients
Species Microscopy + PCRa
positive








P. falciparum 106/144 98/106 (92.5%) 100/106 ND ND 135/144c
P. ovale 26/144 20/26 (76.9%) ND 23/26 ND
P. malariae 12/144 11/12 (91.7%) ND ND 12/12
Negative NDb 5/192 3/192 3/192 3/192 4/192
For the calculation of specificity, blood donors not exposed to malaria (n = 192) were used exposed to malaria (n = 192) were used.
aeach sample was confirmed by PCR.
bND: not done. Blood donors not travelling in malaria-endemic countries were considered as negative (n = 192).
cresults for the combined recombinant for the three species.
Doderer-Lang et al. Malaria Journal 2014, 13:240 Page 4 of 8
http://www.malariajournal.com/content/13/1/240antibodies were detected in almost 90% (259/290) of the
population with the NatELISA. Only two mixed infec-
tions (P. malariae and P. falciparum) were detected by
microscopy, confirmed by PCR, and positive with all re-
combinant proteins (Table 4). Combining the data from
the three assays (RecELISA Total) reveals that almost all
of the investigated population had antibodies against
P. falciparum, P. ovale and P. malariae, suggesting a
non-negligible presence of co-infection (Table 4). In all
blood donors, 85% (1,050/1,235) presented antibodies
directed to native P. falciparum antigen, 94.4% (1,166/
1,235) to P. falciparum recombinant rPfMSP1 and
rPfAMA1, 56.8% (702/1,235) to the P. ovale recombin-
ant rPoMSP1, and 67.5% (834/1,235) to the P. malariae
recombinant rPmMSP1. By summing up all the patients
bearing antibodies directed to recombinant proteins,
the prevalence was 98.8% (1,220/1,235) (Figure 1). These
results demonstrate that the exclusive use of a P. falci-
parum native antigen leads to an underestimation of the
seroprevalence of Plasmodium infection (Table 5). The
173 donors positive under RecELISA and negative under
NatELISA were divided into seven populations depen-
ding on the nature of the recombinant protein detected.
Notably, almost 30% of that population was positive
for P. falciparum, P. ovale and P. malariae (Table 6). In
the RecELISA malaria antibodies-positive population
(n = 1,220), 45.3% of the sera had antibodies recognizing
recombinant proteins from all three species (Figure 2).
According to this assay, 76.1% of the population were
suspected to have an infection with at least two different
species of Plasmodium.Table 2 Recapitulative performances of the assay
Performances NatELISA RecELISA rPfMSP1 + rPfAMA1
Sensitivity 129/144 (89.6%) 100/106 (94.3%)
Specificity 187/192 (97.4%) 189/192 (98.4%)
PPV 96.3% 97.1%
NPV 92.6% 96.9%Seroprevalence of antibodies directed to the three spe-
cies throughout the four seasons of Benin’s semi-
equatorial climate (Figure 3) was investigated. Recognition
of antibodies directed to P. malariae and P. ovale rose
until the end of the LDS. Finally, summing up the data
from the three species, the rate of antibodies was constant
throughout the year (Figure 3). Combining the three spe-
cies’ recombinant proteins improved sensitivity by 10%
over the use of recombinant proteins from P. falciparum
alone. The prevalence of antibodies against the native
P. falciparum antigen dropped significantly at the SRS,
and then increased at the LDS. Distribution of positive
samples according to ELISA index for P. falciparum,
P. malariae and P. ovale recombinant antigens was also
estimated and showed low rates for antibodies directed to
P. ovale and P. malariae species and higher rates for anti-
bodies directed to P. falciparum (Figure 4). No correlation
between parasite density and antibody titre for NatELISA
and RecELISA for the three species was observed.
Discussion
The antigenicity of these recombinant proteins was first
evaluated in patients infected by P. falciparum, P. ovale
and P. malariae in European settings. The analytical pa-
rameters (sensitivity, specificity, PPV, and NPV) using
recombinant proteins were better than those of an ELISA
using a native antigen from P. falciparum. In particular,
the use of recombinant proteins from the P. ovale and
P. malariae species largely enhanced detection rates for
those infections. The efficacy of these new tools was opti-
mized using synthetic genes integrating consensus sequencesRecELISA rPoMSP1 RecELISA rPmMSP1 RecELISA Total
23/26 (88.5%) 12/12 (100%) 135/144 (93.8%)
189/192 (98.4%) 189/192 (98.4%) 188/192 (97.9%)
88.5% 80% 97.1%
98.4% 100% 95.4%
Table 3 Performance of Plasmodium falciparum native
antigen ELISA (NatELISA) versus three specific
recombinant Plasmodium proteins ELISA (RecELISA Total)
RecELISA Total Pos RecELISA Total neg Total
NatELISA pos 127 2 129
NatELISA neg 8 7 15
Total 135 9 144
Total comparative results for malaria-infected patients (n =144) microscopically
diagnosed in a non-endemic country.
Positive RecELISA Total versus positive RecELISA: 135/144 versus 129/144:
Chi-square test, p = 0.2008.
Figure 1 Seroprevalence of antibodies detected by native P.
falciparum or a set of recombinant proteins from Plasmodium
(rPfAMA1 and rMSP1 from P. falciparum, P. ovale and P.
malariae) in 1,235 Beninese blood donors.
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between known strains of each species and optimized for
expression in a prokaryotic system. The biobank used
for validation of the reagent involved sera from patients
specifically infected by one of the three species of patho-
gens. Specificity was high in all cases, reaching an overall
level of 97.9%. In general, the use of various recombinant
antigens resulted in better sensitivity without sacrificing
specificity. However, this technology should be further im-
proved, especially for P. ovale. The surface antigen MSP1
is highly polymorphic due to wide strain variability. This
pitfall in the use of recombinant proteins leading to the
presentation of limited epitopes to humoral response was
previously highlighted [18]. A combined analysis of more
sequences from P. ovale strains, now accessible on
GenBank, might resolve this problem.
The RecELISA’s strong performance allowed the study
of Beninese blood donors. Recent studies using micro-
scopic examination in southern Benin have demon-
strated the presence of mixed infection at the following
rates: 2% P. ovale and 3.1% P. malariae, associated or
not to P. falciparum: 1.2% P. falciparum/P. malariae,
2.4% P. falciparum/P. ovale and 0.1% P. falciparum/P.
malariae/P. ovale [19]. In this study, in a population of
1,235 healthy blood donors, microscopic examination re-
vealed 21.2% P. falciparum and 0.15% P. falciparum/
P. malariae. Similarly, in Burkina Faso, microscopy de-
tected 72.5% P. falciparum, 13.2% P. malariae and 1.8%
P. ovale in a population of 830 children between three
and 15 years old, of which 18.8% were febrile [20]. Mi-
croscopy probably underestimates prevalence, especially
for the cryptic species with low parasitaemia, P. ovaleTable 4 Evaluation of the seroprevalence of three Plasmodium
specific recombinant Plasmodium proteins ELISA (RecELISA) a
(NatELISA) in a population of asymptomatic Benin blood don
falciparum and two mixed infection Plasmodium falciparum a
Results of microscopical examination NatELISA RecELISA rPfM
288 P. falciparum 257/288 (89.2%) 282/288 (97.9%
2 P. malariae and P. falciparum 2/2 (100%) 2/2 (100%)and P. malariae. This diagnostic tool has a detection
threshold of five to 50 parasites/μL [8], while PCR
reaches 0.001 p/μL [15]. A recent review [21] showed
that the use of molecular methods such as PCR, facili-
tates greatly increased P. malariae and P. ovale detection
sensitivity. Snounou et al., using PCR, were able to
detect in a microscopically negative Bissau-Guinean
population, 23.3% P. malariae and 6.9% P. ovale [22]
infection. However, submicroscopic and even sub-PCR
infections do exist and can only be revealed with
serology [11]. Therefore, delimiting transmission areas is
essential [10]. Thus, seroprevalence reflects exposure,
overcoming sampling bias associated with seasonal and
year-to-year variation [11].
However, seroprevalence was exclusively tested using
P. falciparum antigens, neglecting P. ovale and P. malar-
iae. The use of recombinant proteins of P. malariae and
P. ovale allowed revealing high prevalence of antibodies
directed to these cryptic parasites. In Benin, an increased
production of antibodies directed to P. ovale and
P. malariae was observed until the LDS. This may bespecies in blood donors from Benin by the three
nd Plasmodium falciparum native antigen ELISA
ors with positive parasitaemia (n = 290): 288 Plasmodium
nd Plasmodium malariae identified by microscopy






) 195/288 (67.7%) 229/288 (79.9%) 287/288 (99.6%)
2/2 (100%) 2/2 (100%) 2/2 (100%)
Table 5 Comparative results of Plasmodium falciparum
native antigen ELISA (NatELISA) and three specific
recombinant Plasmodium proteins ELISA (RecELISA Total)
for Beninese blood donors (n = 1,235)
RecELISA Total Pos RecELISA Total Neg Total
NatELISA pos 1047 3 1050
NatELISA neg 173 12 185
Total 1220 15 1235
Positive RecELISA Total versus positive NatELISA: 1,220/1,235 versus 1,050/1,235:
Chi-square test, p < 0.0001.
Figure 2 Venn diagram showing a distribution of mixed
malaria infections among 1,220 malaria antibody-positive
Beninese blood donors.
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first infection, as has already been observed [23]. Using
recombinant proteins from P. falciparum (MSP1 and
AMA1), seroprevalence increased after the LRS and
maintained high levels until the LDS, reflecting the long-
lasting presence of IgG directed to rPfAMA1 and
rPfMSP1 antigens. Similarly, the seroprevalence against
P. falciparum recombinant proteins did not vary be-
tween wet and dry seasons in the Gambia [24]. Interest-
ingly, a drop in the recognition of a native P. falciparum
antigen was observed during the SRS. This may be due
to a deficit of MSP1 and AMA1 in the native antigen,
prepared from a synchronized culture in which an 80%
schizont proportion shifted the recognition of the mala-
rial antibodies towards the detection of older stages of
P. falciparum. Another hypothesis is that the variation
in antibody response is due to differences in antigen
concentration and relative proportions of MSP1 in na-
tive and recombinant antigenic preparations.
This work shows that more than half of the studied
population was in contact with other species of Plasmo-
dium in addition to P. falciparum, and that 76% of the
investigated healthy population were exposed to more
than one species. These results indicate that the preva-
lence of non-falciparum species is much higher than
previously estimated. The levels of antibodies directed toTable 6 Distribution of species in the population negative
for the Plasmodium falciparum native antigen ELISA
(NatELISA) and positive for the three specific
recombinant Plasmodium proteins ELISA (RecELISA Total)




Po + Pf 20 11.6%
Po + Pm 3 1.7%
Pm + Pf 28 16.2%
Pf + Po + Pm 48 27.7%
Total 173these two cryptic species is low, possibly due to their
parasitaemia levels. On the contrary, high levels of anti-
bodies against P. falciparum are observed, corresponding
to high parasitaemia levels.
While P. falciparum infection remains the primary con-
cern, the detection of P. ovale and P. malariae is still im-
portant. Although both cause mild infection, P. malariae
can cause chronic nephritic syndrome, leading to adverse
reactions during treatment and a high rate of mortalityFigure 3 Seasonal evolution of seroprevalence for antibodies
detected by native P. falciparum antigen and recombinant
proteins rPfAMA1 + rPfMSP1, rPoMSP1, and rPmMSP1 in 1,235
malaria blood donors in Benin; LRS: long rainy season (May to
July); SDS: short dry season (August to September); SRS: short
rainy season (October to November); LDS: long dry season
(December to March).
Figure 4 Distribution of positive samples according to the
ELISA’s index for P. falciparum, P. malaria and P. ovale
recombinant antigens. The cut-off value was calculated by
multiplying the negative control wells’ average optical density (OD)
by three. The antibody (Ab) index of each sample was calculated
by dividing its OD value by the cut-off value. The sample was
considered positive if the Ab index was >0.7, and negative if the
Ab index was ≤0.7.
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initial exposure, even when the infected population has
left the endemic region [26]. Immune protection against
P. falciparum is not fully effective against P. malariae
[27]. Furthermore, P. malariae is more prevalent when
transmission and infection rates of P. falciparum are
lower, probably because of negative interactions with
P. falciparum; similar interactions with P. ovale might
exist [28]. Positive selection of anti-P. falciparum medica-
tion caused the prevalence of P. malariae to rise for four
years in Burkina Faso. The authors predicted that in the
absence of P. falciparum (ie, due to the effects of a vaccine
directed against P. falciparum), P. malariae parasitaemia
and gametocyte carriage could increase and maintain
severe malaria infection [20].
Conclusion
Given the advent of vaccine campaigns against P. falciparum,
other species must be monitored more closely as their
presence will remain a serious health concern for
exposed populations in endemic countries [29].
In conclusion, with the elimination of malaria back on
the agendas of world agencies, it is necessary to monitor
the effects of anti-malarial measures. In this work a stan-
dardized, sensitive and specific tool was developed that
facilitates measuring and monitoring the transmission
intensity of three Plasmodium species. Antibody preva-
lence for all species of Plasmodium will permit detection
of residual infections and variations in malaria transmis-
sion. Of course, more complex combinations of recom-
binant Plasmodium proteins should be used in futurestudies to avoid the disadvantages of antigenic poly-
morphism and variable individual responsiveness, espe-
cially for P. ovale. These kinds of recombinant tools
could also be used to enhance blood transmission safety
in non-endemic regions [30].
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